Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Candesartan for Migraine Prevention: A Multicentre, Binational, Triple Blind, Placebo Controlled, Parallel Group Study of Two Doses of Candesartan (8 and 16 mg)

NCT04574713 is registered in ClinicalTrials.gov with St. Olavs Hospital as lead sponsor.

NCT NCT04574713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04574713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Candesartan for Migraine Prevention: A Multicentre, Binational, Triple Blind, Placebo Controlled, Parallel Group Study of Two Doses of Candesartan (8 and 16 mg)
Lead sponsor
St. Olavs Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 9, 2021
Completion date
August 8, 2024
Enrollment
450 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

migraine